Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.55 |
| ▸ | CA1 | P00915 | 5/20 | 0.55 |
| ▸ | CA2 | P00918 | 5/20 | 0.55 |
| ▸ | CA9 | Q16790 | 5/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.55 |
| ▸ | CA6 | P23280 | 2/20 | 0.55 |
| ▸ | CA5A | P35218 | 2/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | GABRP | O00591 | 1/20 | 0.55 |
| ▸ | GABRD | O14764 | 1/20 | 0.55 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.55 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.55 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.55 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.55 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.55 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.55 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.55 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.55 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.55 |
| ▸ | GABRE | P78334 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31720460 | 1.00 | CA12 (0.55) | CA12CA1CA2CA9CA14 | |
| SCHEMBL18537752 | 0.85 | CA2 (0.55) | CA12CA1CA2CA9CA14 | |
| SCHEMBL27723107 | 0.82 | P4HA1 (0.61) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL29135135 | 0.81 | CA2 (0.47) | CA12CA1CA2CA9CA14 | |
| SCHEMBL30612303 | 0.81 | P4HTM (0.53) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1017515 | 0.81 | P4HTM (0.53) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL8226755 | 0.81 | NAPRT (0.55) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1713848 | 0.79 | MAPK1 (0.57) | CA12CA1CA2CA9CA14 | |
| SCHEMBL5032688 | 0.78 | CA2 (0.52) | CA12CA1CA2CA9CA14 | |
| Potassium SCHEMBL5035056 | 0.77 | CA2 (0.50) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101321535-A | Heteroaromatic sulfonamide prodrugs | BAYER SCHERING PHARMA AG (DE) | 2008-12-10 | — | — | CN | claimed |
| US-12467928-B2 | N-terminal modifier agents and binders for treating and analyzing peptides | DF PEPTIDE ACQUISITION LLC | 2025-11-11 | — | — | US | disclosed |
| US-20250059220-A1 | SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-02-20 | — | — | US | disclosed |
| US-20240377408-A1 | N-TERMINAL MODIFIER AGENTS AND BINDERS FOR TREATING AND ANALYZING PEPTIDES | DF PEPTIDE ACQUISITION LLC | 2024-11-14 | — | — | US | disclosed |
| EP-4271997-A1 | METALLOENZYMES FOR BIOMOLECULAR RECOGNITION OF N-TERMINAL MODIFIED PEPTIDES | Encodia, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| WO-2023121939-A1 | SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023121939-A1 | SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023111350-A2 | CARBONIC ANHYDRASE IX LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-06-22 | — | — | WO | disclosed |
| US-20220283175-A1 | METALLOENZYMES FOR BIOMOLECULAR RECOGNITION OF N-TERMINAL MODIFIED PEPTIDES | Encodia, Inc. (US) | 2022-09-08 | — | — | US | disclosed |
| US-20220283175-A1 | METALLOENZYMES FOR BIOMOLECULAR RECOGNITION OF N-TERMINAL MODIFIED PEPTIDES | Encodia, Inc. (US) | 2022-09-08 | — | — | US | disclosed |
| WO-2015144605-A1 | BICYCLIC COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-10-01 | — | — | WO | disclosed |
| CN-101987104-A | Ophthalmic composition of heteroaryl sulfamoyl carboxylic ester carbonic anhydrase inhibitor | TIANJIN KINGYORK GROUP CO LTD | 2011-03-23 | — | — | CN | disclosed |
| CN-101321535-A | Heteroaromatic sulfonamide prodrugs | BAYER SCHERING PHARMA AG (DE) | 2008-12-10 | — | — | CN | disclosed |
| EP-1959964-A1 | HETEROAROMATIC SULFONAMIDE PRODRUGS | Bayer Schering Pharma AG (DE) | 2008-08-27 | — | — | EP | disclosed |
| EP-1149091-B1 | 4-(HETEROCYCLYLSULFONAMIDO)-5-METHOXY-6-(2-METHOXYPHENOXY)-2-PHENYL- OR PYRIDYLPYRIMIDINES AS ENDOTHELIN RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-03-19 | — | — | EP | disclosed |
| US-20070135399-A1 | Heteroaromatic sulphonamide prodrugs | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-06-14 | — | — | US | disclosed |
| WO-2007062875-A1 | HETEROAROMATIC SULFONAMIDE PRODRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-06-07 | — | — | WO | disclosed |
| EP-1149091-A1 | 4-(HETEROCYCLYLSULFONAMIDO)-5-METHOXY-6-(2-METHOXYPHENOXY)-2-PHENYL- OR PYRIDYLPYRIMIDINES AS ENDOTHELIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-31 | — | — | EP | disclosed |
| US-6242601-B1 | ENDOTHELIN RECEPTORS INHIBITORS SUCH AS 4-(4-METHOXY-5-(2-METHOXY-PHENOXY)-6-(5-METHYL-PYRIDINE-2-SULF ONYLAMINO)-PYRIMIDIN-2-YL)-PYRIDINE-2-CARBOXYLIC ACID USED TO TREAT CARDIOVASCULAR SYSTEM DISORDERS | HOFFMAN-LA ROCHE INC. | 2001-06-05 | — | — | US | disclosed |
| WO-2000042035-A1 | 4-(HETEROCYCLYLSULFONAMIDO) -5-METHOXY-6- (2-METHOXYPHENOXY) -2-PHENYL- OR PYRIDYLPYRIMIDINES AS ENDOTHELIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135399-A1 | Heteroaromatic sulphonamide prodrugs | SULT2A1, SULT1E1, SULT1A1 | CA12 407/4885CA1 129/4885CA2 29/4885 |
| US-20250059220-A1 | SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF | SULT1E1, TPMT, SULT1A1 | CA12 3290/4885CA1 4104/4885CA2 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.